TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03613675

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video games
Description: The 4 videos games consists of:~* Asthmonaut, a desktop game in which the child navigates through different scenarios and interacts with nine characters to learn about asthma symptoms and management (30 minutes)~* Lung Launcher, a mobile game in which the character encounters different asthma triggers (customizable to the child) and the child has to find the correct preventive method to address each trigger (4 minutes)~* Asthma Heroes, a desktop game where the player interacts with several characters to learn about their symptoms, treatment and context, and collects objects to help them manage their asthma (30 minutes)~* Bloïd, a mobile game where the player uses a pressure sensor as an input device to guide a spacecraft and destroy meteorites in its path (4 minutes).
Study: NCT04162665

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adaptive short course radiation therapy
Description: Radiation must be livered with adaptive planning and MR gating or CBCT breath hold treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care chemotherapy regimen
Description: The recommendations are CAPOX, FOLFOX, or FLT.
Study: NCT02076984

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic incisional or ventral hernia repair

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic incisional or ventral hernia repair
Study: NCT03121729

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: enhanced recovery after surgery
Description: Undergo an enhanced recovery after surgery program
Study: NCT02879539

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MP3000 sound coding strategy or ACE strategy with lower stimulation
Study: NCT03255915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate (TDF)-Emtricitabine (FTC)
Description: TDF-FTC pod-IVR designed to deliver TDF at a target rate of 1 mg d-1 and FTC at a target rate of 2 mg d-1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate (TDF)-Emtricitabine (FTC)
Description: TDF-FTC pod-IVR designed to deliver TDF at a target rate of 1 mg d-1 and FTC at a target rate of 2 mg d-1.
Study: NCT03499899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAG525
Description: LAG525 was a concentrate for solution for intravenous infusion, came in 100mg vials as a liquid formulation for infusion and was dosed at 400mg every 21 days. For all arms, LAG525 was infused first

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAG525
Description: LAG525 was a concentrate for solution for intravenous infusion, came in 100mg vials as a liquid formulation for infusion and was dosed at 400mg every 21 days. For all arms, LAG525 was infused first

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAG525
Description: LAG525 was a concentrate for solution for intravenous infusion, came in 100mg vials as a liquid formulation for infusion and was dosed at 400mg every 21 days. For all arms, LAG525 was infused first

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: Spartalizumab was a concentrate for solution for intravenous infusion, came in 100mg vials as a liquid formulation for infusion and was dosed at 300mg every 21 days. Spartalizumab was infused after LAG525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: Spartalizumab was a concentrate for solution for intravenous infusion, came in 100mg vials as a liquid formulation for infusion and was dosed at 300mg every 21 days. Spartalizumab was infused after LAG525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin was a concentrate for solution for intravenous infusion, came in 100mg/mL and was dosed per area under the curve (AUC) 6 every 21 days. Carboplatin was infused once LAG525 and spartalizumab infusions were completed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin was a concentrate for solution for intravenous infusion, came in 100mg/mL and was dosed per area under the curve (AUC) 6 every 21 days. Carboplatin was infused once LAG525 and spartalizumab infusions were completed
Study: NCT01108341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine hydrochloride
Description: Bendamustine will be administered at 90 mg/m\^2 as a 30-minute intravenous (iv) infusion on days 1 and 2 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Ofatumumab will be administered at 300 mg as an iv infusion on day 1 and 1000 mg on day 8 of cycle 1 and 1000 mg on day 1 of each subsequent cycle.
Study: NCT01710189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TicoVac
Description: Intramuscular immunisation to right deltoid muscle (Group 1) or right upper anterolateral thigh muscle (Group 2).
Study: NCT00674466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.5 mg or 2.0 mg CJC-1134-PC
Description: twice-a-week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.5 mg or 2.0 mg CJC-1134-PC
Description: twice-a-week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice-a-week
Study: NCT03167684

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oral appliance therapy
Description: Fitted oral appliance
Study: NCT03976466

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Antibiotic local prophylaxis with medicated calcium sulfate beads
Description: Antibiotic prophylaxis in patients with non-modifiable risk factors for periprosthetic joint infection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Classical parenteral antibiotic prophylaxis
Description: Antibiotic prophylaxis in patients with non-modifiable risk factors for periprosthetic joint infection
Study: NCT01557322

Intervention type: BIOLOGICAL
Intervention: etanercept
Description: This is a Non-interventional study. The data is being analyzed retrospectively. The data consists of 2 cohorts; biologic and non-biologic

Intervention type: DRUG
Intervention: methotrexate (MTX)
Description: This is a Non-interventional study. The data is being analyzed retrospectively. The data consists of 2 cohorts; biologic and non-biologic
Study: NCT02716337

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Addition of human milk fortifiers according to human milk analysis
Study: NCT04199260

Intervention type: DEVICE
Intervention: papilocare vaginal gel
Description: Papilocare is a gel vaginally administered by a single-dose cannula. Vaginal gel formulation is effective as a local treatment with controlled systemic absorption and rapid and efficient distribution
Study: NCT01265901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: As per label.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: As per label.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Intradermal injection of GM-CSF as adjuvant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: One single low-dose i.v. infusion prior to the first vaccination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMA901
Description: Intradermal vaccinations with IMA901 vaccine.
Study: NCT01599923

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antivenin Centruroides (scorpion) equine immune F(ab')2
Description: 3 vials of Alacramyn reconstituted in 50 ml of normal saline as an IV infusion over 10 minutes.
Study: NCT03042598

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biphasic Cuirass Ventilation
Description: The RTX Respirator will be applied to the patient's chest to provide non-invasive ventilatory support using a Biphasic Cuirass Ventilation technology to increase the safe apnic period during intubation.
Study: NCT02201056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-935
Description: TAK-935 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-935
Description: TAK-935 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-935
Description: TAK-935 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-935
Description: TAK-935 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-935
Description: TAK-935 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-935
Description: TAK-935 oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-935 placebo-matching oral solution
Study: NCT01931735

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Randomized Meniscectomy
Description: Arthroscopic meniscectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Randomized Lavage
Description: Arthroscopic Lavage

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard of Care Meniscectomy Pre-Amend
Description: Arthroscopic meniscectomy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard of Care Meniscectomy Post-Amend
Description: Arthroscopic meniscectomy
Study: NCT03515382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1690
Description: A single oral dose of GLPG1690.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1690
Description: A single oral dose of GLPG1690.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1690
Description: A single oral dose of GLPG1690.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: A single oral dose of itraconazole.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: A single oral dose of voriconazole.
Study: NCT01970787

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation (RFA) using the HALO Ablation System
Study: NCT01395823

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: ergocalciferol supplementation
Description: 50,000 IU given either weekly; weekly for 3 months then monthly for 3 months; monthly

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo pill given weekly, weekly for 3 months then monthly for 3 months; monthly
Study: NCT03033459

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Motivational Interviewing (MI) is a psychosocial intervention designed to help individuals increase readiness for behavior change by increasing intrinsic motivation and resolving ambivalence. MI founders MI conversations help clients change behavior through identifying and resolving discrepancies between goal behaviors and actual behaviors. Behavior change is promoted through the elicitation of change talk, or client-verbalized arguments for change. In MI, change talk is elicited through two major components: the therapeutic relationship, or the embodiment of the spirit of MI, and technical skill.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation Control
Description: Psychoeducation on infant development, age 0-15 months, brief education on breastfeeding.
Study: NCT05211271

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment of cervical neoplasia by thermal ablation
Description: Women screened for cervical cancer by visual inspection with diluted acetic acid (VIA) presenting lesions eligible for ablative treatment were treated by thermal ablation. The treatment consisted in applying the probe on the lesion for 45 seconds at 100 degrees Celsius, with one to up to five applications depending on the lesion size. Following treatment, women were inquired about the pain level during the procedure, their satisfaction level of the procedure and whether they would recommend this treatment to their relatives. Women had a follow-up visit at 6 weeks to assess any complication of the procedure. Women were rescreened at 12 months, to evaluate the cure rate and any long-term adverse events.
Study: NCT02725125

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EPCAM-targeted CAR-T cells
Description: This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-EPCAM-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
Study: NCT01677143

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine 5mg/ml
Description: 5 ml in trocar area

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 5mg/ml
Description: 5 ml in trocar area
Study: NCT03951974

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Emotion Regulation Strategy Development
Description: Participants will work one-on-one with an interventionist to develop goals (in the form of implementation intentions) to develop social emotion regulation strategies to combat frequent emotional challenges.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: Participants will work one-on-one with an interventionist to report on their frequent emotional challenges, and report the emotion regulation strategies that they frequently use to combat them.
Study: NCT03522714

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fluid Immersion Simulation System
Description: Dolphin Fluid Immersion Simulation® System Mattress will be used

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air Fluidized Bed System
Description: Air Fluidized Bed (Clinitron) will be used.
Study: NCT00779974

Intervention type: OTHER
Intervention: Evaluation
Description: For this research study each enrolled subject will have a clinical exam, including range of motion (ROM), and strength testing. The lift off and belly compression tests will be performed. An ultrasound of the shoulder will be done to determine the integrity of the subscapularis tendon. An EMG will be done to determine functionality of the subscapularis.
Study: NCT00953537

Intervention type: DRUG
Group type: OTHER
Intervention: capecitabine

Intervention type: OTHER
Group type: OTHER
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Group type: OTHER
Intervention: pharmacological study
Study: NCT04520802

Intervention type: DIAGNOSTIC_TEST
Intervention: 18F-DPA-714 PET/CT neuroimaging
Description: * Pre- and postoperative neuroimaging using 18F-DPA-714 PET/CT and brain MRI.~* Longitudinal neuropsychological examinations (up to 6 months postoperatively)~* Blood samples are drawn to assess the severity of the systemic inflammatory response

Intervention type: DIAGNOSTIC_TEST
Intervention: 18F-DPA-714 PET/CT neuroimaging
Description: * Pre- and postoperative neuroimaging using 18F-DPA-714 PET/CT and brain MRI.~* Longitudinal neuropsychological examinations (up to 6 months postoperatively)~* Blood samples are drawn to assess the severity of the systemic inflammatory response
Study: NCT02404389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Treatment
Description: Topical application for two treatment cycles with twice daily applications, separated by a 4 week treatment pause and followed by 8 week treatment free follow-up.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Treatment
Description: Topical application for two treatment cycles with twice daily applications, separated by a 4 week treatment pause and followed by 8 week treatment free follow-up.
Study: NCT03255915

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A placebo pod-IVR containing microcrystalline cellulose pods.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A placebo pod-IVR containing microcrystalline cellulose pods.
Study: NCT03195127

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multimodal physical therapy
Description: Consist of limb strengthening exercises, endurance training, and balance/coordination drills. These exercises and training maneuvers may involve the use of handheld weights, nautilus weight equipment, elastic exercise bands, stationary exercise machines (recumbent exercise cycles, hand ergometer cycles), or treadmills. If the subject is fit enough, Tai Chi may be added to as a training method to help improve your balance and strength. In addition, the subject will be asked to wear an accelerometer on their wrist
Study: NCT03334747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAE609
Description: Exploration of different doses of KAE609 to establish safety profile.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAE609
Description: Exploration of different doses of KAE609 to establish safety profile.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAE609
Description: Exploration of different doses of KAE609 to establish safety profile.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAE609
Description: Exploration of different doses of KAE609 to establish safety profile.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAE609
Description: Exploration of different doses of KAE609 to establish safety profile.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAE609
Description: Exploration of different doses of KAE609 to establish safety profile.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAE609
Description: Exploration of different doses of KAE609 to establish safety profile.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAE609
Description: Exploration of different doses of KAE609 to establish safety profile.
Study: NCT02404389

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Investigational Treatment
Description: Topical application for two treatment cycles with twice daily applications, separated by a 4 week treatment pause and followed by 8 week treatment free follow-up.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Investigational Treatment
Description: Topical application for two treatment cycles with twice daily applications, separated by a 4 week treatment pause and followed by 8 week treatment free follow-up.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator
Description: Topical treatment with Aldara 3 times per week. The group will be open-label, but however blinded to the efficacy assessor, and followed by 8 week treatment free follow-up.
Study: NCT02947438

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPREX®
Description: Recombinant human erythropoietin falls under the pharmacological class of haematopoietic / anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.~Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPIAO®
Description: Recombinant human erythropoietin falls under the pharmacological class of haematopoietic / anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.~Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000.
Study: NCT04238312

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RESPeRATE™
Description: Fifty-five anxious pediatric dental patients received a breathing session of 10 minutes, using the RESPeRATE™ device.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tell, Show and Do technique
Description: Fifty-five anxious pediatric dental patients received a traditional behavior management technique (Tell-Show-Do).
Study: NCT01592162

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol (Astra-Zeneca), NaCl 0.9%
Description: propofol administered by a closed-loop system and saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol 1% (Astra-Zeneca) and remifentanil
Description: propofol administered by a closed-loop system and remifentanil (2 ng/ml, target controled infusion)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol 1% (Astra-Zeneca) and remifentanil
Description: propofol administered by a closed-loop system and remifentanil (4 ng/ml, target controled infusion)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol (Astra-Zeneca), NaCl 0.9%
Description: propofol administered by a closed-loop system and saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol (Astra-Zeneca) and remifentanil
Description: propofol administered by a closed-loop system and remifentanil (2 ng/ml, target controled infusion)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol (Astra-Zeneca) and remifentanil
Description: propofol administered by a closed-loop system and remifentanil (4 ng/ml, target controled infusion)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol (B-Braun) and NaCl 0.9%
Description: propofol administered by a closed-loop system and saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol (B-Braun) and remifentanil
Description: propofol administered by a closed-loop system and remifentanil (2 ng/ml, target controled infusion)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol (B-Braun) and remifentanil
Description: propofol administered by a closed-loop system and remifentanil (4 ng/ml, target controled infusion)
Study: NCT00061516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BETAXON (levobetaxolol HCl)
Description: levobetaxolol suspension, 0.5%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZOPT (brinzolamide)
Description: brinzolamide suspension, 1%
Study: NCT04339647

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The SIMS programme
Description: The intervention targets 5-6-year-old preschool children and their parents. Apart from the usual care, 5-6-year-old children receive oral health lessons and supervised daily tooth brushing (1000ppm F) at school over a period of 6 months, as well as home tooth brushing supervision by parents for 6 months. Parents/guardians attend a meeting with a DT team at school to discuss on child's oral health status, receive OHE and free toothbrush and fluoride toothpaste (1000ppm F) for child home tooth brushing, and receive 10 oral health infographic messages from DT over a period of 5 months (with printed versions available).
Study: NCT03032328

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D supplement
Description: Patients will be given a dose of vitamin D for at least 2 months
Study: NCT03334747

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coartem
Description: Control Arm
Study: NCT00598637

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus-eluting stent (Xience)
Description: stent is implanted due to randomization
Study: NCT00327769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 250 mg intramuscular injection